Most people who search for bimagrumab arrive with the wrong mental model. They have seen the headline — a drug that strips fat while adding muscle, the mirror image of what a GLP-1 does to body composition — and they want to know where to buy it, what it costs, how to dose it. Bimagrumab does not work that way. It is not a peptide, it cannot be compounded, no vendor or telehealth clinic legitimately sells it, and it has never been approved for anything. It is also a drug that failed its pivotal trial, in a way that still constrains how you should read every body-composition number attached to it. This page is about that tension: a mechanism that clearly does something real, and an evidence base that has repeatedly declined to show that the something matters.
What bimagrumab actually is — and what it is not
Skeletal muscle is held in check by a family of TGF-β ligands — myostatin, activin A, GDF11 — that all signal through the same two receptors, activin type IIA and type IIB (ActRIIA and ActRIIB). Bimagrumab is a fully human monoclonal antibody engineered at Novartis to sit on those receptors and block every one of those ligands at once. In the paper that introduced it, the antibody produced more muscle growth than a myostatin inhibitor alone, and added further hypertrophy even in mice that had no functional myostatin at all — direct evidence that it works above and beyond myostatin blockade.[1] The same receptor family turns out to regulate fat: activin signalling through ActRII in adipose tissue restrains lipolysis, which is why blocking the receptor mobilises fat rather than merely sparing muscle.[10]
Four practical consequences follow from the word antibody, and they answer most of the questions people actually have:
- It is not a peptide. Bimagrumab is a ~150 kDa immunoglobulin grown in mammalian cell culture. It cannot be made by solid-phase peptide synthesis, which is what “research peptide” suppliers do. Anything sold online under this name is not bimagrumab.
- It is not compoundable. Compounding pharmacies work from approved drugs or from bulk substances that FDA permits. Bimagrumab is neither: it has no approval anywhere, and it is a biologic. There is no legal route by which a 503A or 503B pharmacy could supply it.
- It is dosed like a biologic, not a daily injectable. The trials use intravenous infusions of 10–30 mg/kg spaced weeks apart; a phase 1 study showed weekly subcutaneous dosing can match monthly IV exposure, with roughly 40% subcutaneous bioavailability and target-mediated clearance.[13] This is infusion-suite pharmacology.
- It is not a myostatin peptide. Readers frequently conflate it with follistatin, “follistatin-344” and other myostatin-adjacent compounds sold as injectables. Those are a different class with a far weaker evidence base — see follistatin: the actual evidence. Bimagrumab is the one molecule in this space with large randomized trials behind it, which is exactly why its failures are informative.
The failure that shapes everything: RESILIENT
Bimagrumab’s first serious clinical bet was sporadic inclusion body myositis (sIBM), a progressive muscle disease with no effective treatment. RESILIENT was, at the time, the largest randomized controlled trial ever run in the condition: 251 participants at 38 academic sites across Australia, Europe, Japan and the USA, randomized to bimagrumab at 10, 3 or 1 mg/kg or placebo, infused every four weeks for at least 48 weeks. The primary endpoint was 6-minute walk distance at week 52.
It missed, at every dose. The treatment difference versus placebo was 17.6 m for 10 mg/kg (p = 0.22), 18.6 m for 3 mg/kg (p = 0.19) and −1.3 m for 1 mg/kg (p = 0.93).[2] Safety was unremarkable relative to placebo, but muscle spasms (51% at the top dose vs 21% on placebo) and diarrhoea (52% vs 18%) were clearly drug-related. The two-year extension study is the part worth dwelling on: 211 participants continued, walk distance deteriorated progressively from week 24 to week 104 in every group including bimagrumab, and the extension was terminated early because the core study had failed.[3] The authors graded it Class IV evidence that long-term bimagrumab is safe, well tolerated, and provides no meaningful functional benefit.
The same dissociation, four separate times
RESILIENT is not an isolated miss. Across four different populations, in four independent trials — sarcopenic adults over 70,[4] patients with COPD and low muscle mass,[5] and older adults recovering from hip-fracture surgery[6] — bimagrumab did the mechanistic thing it was designed to do, and the functional endpoint stayed flat.
| Trial and population | What happened to mass | What happened to function |
|---|---|---|
| RESILIENT — sporadic inclusion body myositis (n = 251, 52 wk) | Not the primary endpoint; thigh muscle volume rose in earlier sIBM work | 6-minute walk distance: no difference at any dose (p = 0.19–0.93) |
| Sarcopenia in community-dwelling adults ≥70 (n = 180, 24 wk) | Lean body mass +7% vs +1% on placebo (p < 0.001) | Short Physical Performance Battery +1.34 vs +1.03 (p = .13); gait speed and 6MWD also non-significant |
| COPD with low muscle mass (n = 67, 24 wk) | Thigh muscle volume +5.0% vs −1.3% at week 24 (p < 0.001) | 6-minute walk distance did not increase significantly in either group |
| Recovery after hip-fracture surgery (n = 250, 24 wk) | Lean body mass +2.8 kg at 700 mg vs +0.2 kg placebo (p < 0.0001) | Habitual gait speed and physical-performance battery: no significant difference |
A 2024 meta-analysis of seven randomized trials put a number on both halves. Bimagrumab increased thigh muscle volume by 5.29% and fat-free mass by 1.90 kg, and cut fat mass by 4.55 kg — all highly significant. And it found no significant improvement in muscle strength, gait speed or 6-minute walk distance, except in participants who started out slowest.[7] That last clause is the only real signal of functional benefit anywhere in the record, and it is a subgroup observation, not a finding.
Why the disconnect? The honest answer is that nobody has demonstrated it. The plausible explanations — that the added tissue is not fully contractile, that ceiling effects blunt the walk tests, that six months is too short, that in sIBM the underlying degeneration simply outruns any anabolic push — are hypotheses. What is established is the pattern: bimagrumab moves the scan, not the stopwatch.
Why obesity medicine picked it back up
The fat-loss effect was noticed as a side observation and then chased deliberately. In a small mechanistic study, 16 insulin-resistant adults given a single dose gained 2.7% lean mass and lost 7.9% fat mass by week 10 with essentially no change in body weight, alongside a 0.21-point HbA1c reduction and a 20–40% improvement in insulin sensitivity depending on the method — all without any diet or exercise intervention.[8] That result is what reframed bimagrumab from a muscle drug into a body-composition drug.
The pivotal demonstration came in 2021. Seventy-five adults with type 2 diabetes and a BMI of 28–40 received monthly intravenous bimagrumab (10 mg/kg, capped at 1,200 mg) or placebo for 48 weeks, both arms with diet and exercise counselling. At week 48, versus placebo:
- Fat mass −20.5% (−7.5 kg), against −0.5% on placebo
- Lean mass +3.6% (+1.7 kg), against −0.8% on placebo
- Waist circumference −9.0 cm, against +0.5 cm
- HbA1c −0.76 percentage points, against −0.04
- Body weight −6.5% (−5.9 kg), against −0.8%
All at p < 0.005 or better.[9] Read the weight column and the fat column together and the mechanism is obvious: bimagrumab shed 7.5 kg of fat but only 5.9 kg of weight, because it was putting lean tissue back on at the same time. That is the inverse of what happens on incretin therapy, where roughly 25–40% of the weight lost is lean tissue — the issue we cover in GLP-1 medications and muscle.
Two caveats belong right here. The trial randomized 75 people and only 58 finished, so these are precise-looking numbers from a small completer analysis; the published paper carries two subsequent errata. And a 2026 systematic review pooling the four randomized trials in metabolic populations (268 participants total) reports the same benefits at more modest magnitude — weight −4.85 kg, fat mass −4.72 kg — alongside an LDL cholesterol increase of 0.47 mmol/L and sharply elevated relative risks for discontinuation (RR 5.75), muscle spasms (RR 10.44) and diarrhoea (RR 4.91).[11] The upside and the tolerability cost are the same size finding.
BELIEVE: what happens when you add it to a GLP-1
The obvious experiment — block ActRII while an incretin drives the calorie deficit — was first run in diet-induced obese mice, where bimagrumab plus semaglutide produced greater fat loss than either alone while preserving the lean mass that semaglutide alone destroyed.[15] The human version is BELIEVE: a double-blind, placebo-controlled phase 2 trial in 507 adults with obesity, randomized across nine arms — placebo, bimagrumab at 10 or 30 mg/kg IV every 12 weeks, semaglutide at 1.0 or 2.4 mg weekly, and every combination — for 48 weeks, with an open-label extension to week 72.[10]
At week 48, least-squares mean weight change was −9.3 kg on bimagrumab 30 mg/kg, −14.2 kg on semaglutide 2.4 mg, and −17.8 kg on the high-dose combination, against −3.3 kg on placebo. But the interesting column is what the weight was made of. The trial reports a “fat loss index” — the share of total tissue change accounted for by fat:
| Week 72 outcome | Bimagrumab 30 mg/kg | Semaglutide 2.4 mg | Both |
|---|---|---|---|
| Body weight | −10.8% | −15.7% | −22.1% |
| Total body fat mass | −28.5% | −27.8% | −45.7% |
| Total body lean mass | +2.5% | −7.4% | −2.9% |
| Share of weight lost that was fat | 100% | 75.6% | 92.2% |
This is a genuinely striking result and the reason bimagrumab is in the conversation at all. It is also a phase 2 result, and it should be read with four specific reservations that the investigators state themselves.[10] The semaglutide arms were open-label, because no matched placebo was available at trial start — participants knew whether they were getting the drug everyone had heard of. All week-72 analyses were post hoc with no multiplicity adjustment, so the authors explicitly warn they should not be used to infer definitive treatment effects. Body composition was measured by DXA rather than MRI, so “lean mass” includes visceral organs and water, not just muscle. And grip strength and patient-reported physical function did not improve in any group except one combination arm — the dissociation from RESILIENT, showing up again in a completely different population.
The tolerability picture also deserves to be stated plainly, because the body-composition chart hides it. Treatment discontinuation due to adverse events was 14.0–21.4% in the bimagrumab monotherapy arms, versus 3.6–8.8% on semaglutide and 3.6% on placebo. Muscle spasms were the reason five participants quit; acne accounted for four. Bimagrumab-containing arms showed rises in alkaline phosphatase and creatine kinase, transient ALT and AST elevations, and LDL cholesterol up 17.6% at week 72 on monotherapy (it normalised when semaglutide 2.4 mg was co-administered). Total hip bone mineral density fell 2.2–2.3% in the high-dose combination arms — comparable to semaglutide alone, but a signal to watch in older patients.[10]
What is actually being tested next
The IV-every-12-weeks regimen used in BELIEVE was never the commercial plan; the investigators note that the loading doses likely contributed to the early lab abnormalities and adverse events, and that subcutaneous dosing should attenuate them.[10][13] The successor trial is NCT06643728, a Lilly phase 2 study of bimagrumab and tirzepatide, alone or in combination, in 252 adults with obesity or overweight without type 2 diabetes — both drugs given subcutaneously, with percent change in body weight as the primary endpoint. It reached actual primary completion in January 2026 and is listed as active, not recruiting, with estimated study completion in 2027.[17] As of this writing no results from that trial have been published or posted — anyone quoting bimagrumab-plus-tirzepatide numbers is quoting something that has not been reported. A separate investigator-initiated trial at Massachusetts General Hospital is examining tirzepatide and bimagrumab on body composition, insulin sensitivity and bone, with estimated completion in 2029.[18]
One safety question has already been answered ahead of those readouts. Because ActRII blockade grows skeletal muscle, the obvious worry is what it does to cardiac muscle. A randomized, placebo-controlled study in 68 healthy adults aged 60–86 used cardiac MRI over six months of bimagrumab 10 mg/kg and found no clinically relevant change in left ventricular mass index or ejection fraction, while lean body mass rose 5.5% and fat mass fell 14%.[12] That is a meaningful de-risking of the most-cited theoretical objection — in 68 healthy people over six months, which is the appropriate size of the reassurance.
Safety: blocking a growth-restraint pathway is not free
Across the programme the recurring, clearly drug-attributable adverse events are muscle spasms and cramps, diarrhoea, and acne.[2][10] Two less obvious findings are worth knowing:
- It blocks more than myostatin, and the endocrine system notices. Activins act on pituitary gonadotroph cells, so an ActRII antibody hits them too. In healthy adults aged 55–75, bimagrumab reduced FSH by 42.16 IU/L (p < .001) and nudged LH upward in women but not in men; gonadal and adrenal androgen levels were unaffected, and the effect reversed as the antibody cleared.[14] Reversible, but a reminder that this is a receptor-family blockade, not a single-ligand tool.
- The metabolic benefit may be species-specific — in the wrong direction. A 2025 mouse study of ActRIIA/IIB antibody blockade reproduced the muscle findings (+20% muscle mass, +30% soleus strength, −8% fat) but found glucose intolerance, cardiac hypertrophy with glycogen accumulation, elevated hepatic triacylglycerol, and a large drop in voluntary running.[16] The authors flag this explicitly as contradicting the improved glycaemic control seen in humans. Human HbA1c data currently look better than the mouse data — but it is an unresolved discrepancy in a pathway that touches heart, liver and muscle at once, and it is not settled by 48-week trials in a few hundred people.
The honest bottom line
Bimagrumab is the most rigorously tested muscle-anabolic agent that exists, and its record is unusually clean about what it can and cannot do. It reliably adds lean mass and strips fat, in multiple populations, measured by DXA and MRI, in randomized placebo-controlled trials. It has never been shown to make anyone walk faster, walk farther, or score better on a physical-performance battery — not in inclusion body myositis, not in sarcopenia, not in COPD, not after hip fracture, and not, on grip strength, in BELIEVE.
That makes its current role coherent and narrow. In obesity, the endpoint is body composition: if the goal is to lose fat without giving up 25–40% of the loss as lean tissue, bimagrumab is the only agent with randomized human evidence that it changes that ratio, and BELIEVE is the best demonstration to date.[10] That is a real and important finding. It is not the same as evidence that the preserved lean mass makes people stronger, healthier, or longer-lived, which remains unmeasured. Semaglutide, by contrast, is an approved drug with prescribing information, outcome trials and a known label;[19] bimagrumab has phase 2 data and a corporate owner.
For anyone reading this because they want it: the answer is that it does not exist outside a clinical trial, and the honest next step is either the protein-and-resistance-training approach that already has evidence behind it, or ClinicalTrials.gov.
This article is research information, not medical advice. Bimagrumab is an investigational monoclonal antibody with no FDA approval for any indication; it is not available by prescription, cannot be compounded by a pharmacy, and is not a peptide that any research-chemical supplier can legitimately sell. Every dose and outcome described here comes from a clinical trial conducted under medical supervision, and none of it constitutes a dosing recommendation. Any product marketed to consumers under this name should be assumed not to be bimagrumab. If you are concerned about muscle loss during weight loss, discuss it with a licensed clinician.